CAS 635318-55-7

Pomaglumetad methionil anhydrous

CAS: 635318-55-7

LY2140023, potential schizophrenia treatment, is an oral prodrug of LY404039, a selective mGlu2/3 agonist.

Fórmula: C₁₂H₁₈N₂O₇S₂

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 366.41

Ref: TM-T11907

LY2140023

CAS: 635318-55-7

LY2140023 is a novel drug that acts as an agonist of the metabotropic glutamate receptor mGlu2. It has been shown to be efficacious in animal models for the treatment of symptoms caused by disorders such as Parkinson’s disease, schizophrenia, and depression. LY2140023 is an oral prodrug that is metabolized into its active form in the liver. The drug may have potential for use in combination with other drugs to treat conditions such as Alzheimer's disease or stroke. LY2140023 has also been shown to increase locomotor activity and improve cognition in mice with a brain lesion. The long-term efficacy of the drug has not yet been established, but it has potential as a pharmacological agent for treating symptoms caused by disorders such as Parkinson’s disease, schizophrenia, and depression.

Fórmula: C₁₂H₁₈N₂O₇S₂

Pureza: Min. 95%

Peso molecular: 366.41 g/mol

Ref: 3D-FL32644

LY 2140023

Produto Controlado

CAS: 635318-55-7

Fórmula: C₁₂H₁₈N₂O₇S₂

Cor e Forma: Neat

Peso molecular: 366.41

Ref: TR-L073880